The FDA has approved trospium chloride extended-release capsules (Sanctura XL) for once-daily treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
The FDA has approved trospium chloride extended-release capsules (Sanctura XL) for once-daily treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
The FDA approval was based on a review of data from clinical studies conducted across the United States involving approximately 1,300 patients. The drug was well tolerated, and the most commonly reported side effects in phase III trials were dry mouth (10.7% for extended-release trospium vs. 3.7% for placebo) and constipation (8.5% vs. 1.5%).
“The introduction of Sanctura XR will provide overactive bladder patients an efficacious treatment combined with excellent tolerability,” said lead author David R. Staskin, MD, of New York Presbyterian Hospital and Weill-Cornell Medical College, New York. “The efficacy of the prior formulation is preserved as well as the lack of metabolic drug-drug interactions, while the dry-mouth rate is half of the prior formulation.”
Malpractice Consult: How likely are you to face a medical malpractice lawsuit?
July 23rd 2024"Although there is a good chance that you will face allegations of medical negligence at some point in your career, it is unlikely that you will ever be found liable by a jury," writes Victoria L. Neikam, Esq.
UK study of AI-based software for prostate cancer detection expands
July 22nd 2024"We will be looking not only at how well this software performs in a busy clinical setting and whether diagnostic accuracy and efficiency improves, but also assessing the experience of clinicians and patients, and looking at the impact on workflow," says Clare Verrill, BM, FRCPath, MMedEd.